ARS Pharmaceuticals

ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. The company focuses on developing patient-friendly, needle-free treatments for severe allergic reactions. Richard Lowenthal, a co-founder with a background in drug delivery, serves as President and CEO. ARS's lead product is neffy, a nasal spray formulation of epinephrine. The company received regulatory approval for neffy from the FDA in August 2024 for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 30 kilograms or more. Beyond the initial approval, ARS is pursuing label expansions for younger children and exploring additional indications. The company's strategy centers on replacing the traditional epinephrine auto-injector with a more convenient, temperature-stable, needle-free alternative, targeting the global allergic reaction treatment market. In August 2024, ARS achieved a watershed moment when neffy secured full regulatory approval in the United States, becoming the first needle-free epinephrine option available to patients. The product was subsequently launched in the U.S. market. Further regulatory applications were under review in the European Union and elsewhere, underscoring a global commercial strategy. The structural differentiator for ARS lies in its single-product focus and drug-delivery platform. The entire organization is aligned behind replacing the epinephrine auto-injector standard of care, a device architecture that had remained largely unchanged for decades. Its value is tied entirely to neffy's commercial adoption, creating a binary outcome profile distinct from diversified pharmaceutical companies.